Jan Klatt

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet et al. · The Lancet · 2018 · 470 citations · Full text

Medicine, Neurology, Pharmacology +9

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

Uwe Reuter, Marc Ehrlich, Astrid Gendolla et al. · Cephalalgia · 2021 · 178 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention

Messoud Ashina, David Doležil, Jo Bonner et al. · Cephalalgia · 2020 · 171 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Messoud Ashina, Stewart J. Tepper, Jan Lewis Brandes et al. · Cephalalgia · 2018 · 157 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Peter J. Goadsby, Koen Paemeleire, Gregor Broessner et al. · Cephalalgia · 2019 · 129 citations

Pharmacy, Pharmacology, Pharmacotherapy +15